Everyone
Michael Pehl, MSc
Chief Executive Officer
+25 years of global pharmaceutical & biotech leadership experience. Former CEO of GEMoaB, CEO of Immunomedics, and President of Hematology & Oncology at Celgene
John Doe, PhD
CSO
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Carmel M. Lynch, PhD
Chief Development Officer
+25 years of experience in biotechnology, spanning from discovery research to clinical development, with an emphasis in translational medicine. +15 years specializing in ADCs; led Nonclinical and Clinical Pharmacology development of Adcetris(tm) ADC at SeaGen from pre-IND to approval in 2011
Pernille Hemmingsen, PhD
Chief Technology Officer
+20 years experience in the pharmaceutical industry. Former VP, Global Product Development and Supply at Savara ApS. 5 years at Genmab, leading ADC CMC and manufacturing, from non-clinical to phase II development
Christoffer Nielsen, PhD
Chief Operating Officer & Co-founder
Established the scientific project on utilization of receptors for targeted drug delivery by ADCs at The Finsen Laboratory, which became Adcendo. Molecular Biologist by training, founding CTO of Adcendo from 2017-2021